Assoc Prof Tom Weickert with CATS study participant Leanne and research assistant Isabella Jacomb

CATS

RESEARCH STUDY

CANAKINUMAB ADD-ON TREATMENT FOR SCHIZOPHRENIA (CATS) STUDY

Canakinumab adjunctive treatment to reduce symptoms and improve cognition in people with schizophrenia displaying elevated blood inflammatory markers

HREC Approval Number: 14/072
What is the purpose of this study?

You are invited to participate in a research study of a human immune cell-line antibody on language, memory, and symptoms of schizophrenia. This human immune cell-line antibody, canakinumab, is a class of medication that decreases the levels of the protein interleukin-1beta (IL-1β). The IL-1β protein is produced in response to inflammation in your body and canakinumab can decrease IL-1β protein and inflammation by blocking the pathway. We hope to learn how this human immune cell-line antibody, in addition to your normal antipsychotic medication, can also improve thought processing and reduce symptoms in people with schizophrenia, and to determine if this human immune cell-line antibody can be used as a new therapeutic treatment for thinking problems and symptoms in people with schizophrenia.

What does the study involve?

The study involves a one-time injection of canakinumab or placebo and 6 monitoring assessment visits over a 4-month period. The assessments include:

  • An in-person screening interview
  • Cognitive tests
  • Symptom assessments
  • Medical examinations and clinical interviews
  • Blood collection
  • Structural and functional MRI
Who can enrol?

Men or women age 18-55 years old with a diagnosis of schizophrenia or schizoaffective disorder. You must be taking antipsychotic medication for at least one year but you must not be taking clozapine and have no other psychiatric diagnoses, history of seizures, substance abuse (within past 3 years), head injury or loss of consciousness, central nervous system infections or other serious or chronic infections, and if a woman, you cannot be pregnant.

Will I be reimbursed?

Your participation in this study may have associated expenses. Reimbursement will be provided for your time and for out-of-pocket expenses, such as travel to the centre.

Contact Information

If you have any questions, or if you are interested in participating, please feel free to contact a member of the research team:

Isabella Jacomb at 02 9399 1858, email: i.jacomb@neura.edu.au

Dr Thomas W Weickert at 02 9399 1730, fax: 02 9399 1034, email: t.weickert@neura.edu.au

See what’s going on at NeuRA

FEEL THE BUZZ IN THE AIR? US TOO.

'I've got the best job for you dad. Your shaky arm will be perfect for it!'

Children… honest and insightful. Their innocence warms the heart. But what words do you use to explain to a child that daddy has an incurable brain disease? What words tell them that in time he may not be able to play football in the park, let alone feed himself? What words help them understand that in the later stages, dementia may also strike? Aged just 36, this was the reality that faced Steve Hartley. Parkinson's disease didn't care he was a fit, healthy, a young dad and devoted husband. It also didn't seem to care his family had no history of it. The key to defeating Parkinson's disease is early intervention, and thanks to a global research team, led by NeuRA, we're pleased to announce that early intervention may be possible. Your support, alongside national and international foundations Shake it Up Australia and the Michael J Fox Foundation, researchers have discovered that a special protein, found in people with a family history of the disease increases prior to Parkinson’s symptoms developing. This is an incredible step forward, because it means that drug therapies, aimed at blocking the increase in the protein, can be administered much earlier – even before symptoms strike. The next step is to understand when to give the drug therapies and which people will most benefit from it. But we need your help. A gift today will support vital research and in time help medical professionals around the world treat Parkinson’s disease sooner, with much better health outcomes. Thank you, in advance, for your support.  
APPEAL